Clear market notes built around the JSE, the rand, and what matters locally.

2026-10-02 10:30 • The Motley Fool Mixed Axe Cap view: Selective

In anticipation of a potential bear market driven by an AI spending slowdown, the article identifies Oracle and CoreWeave as vulnerable stocks due to their heavy reliance on expensive debt to fund growth in AI infrastructure. Conversely, Berkshire Hathaway is positioned as a defensive investment with $365 billion in cash reserves to capitalize on market downturns.

Axe note: Heavy debt loads make Oracle and CoreWeave risky ahead of a possible AI-driven bear market, while Berkshire Hathaway’s cash reserves offer safety.

2026-10-02 10:15 • The Motley Fool Positive Axe Cap view: Selective

Viking Therapeutics' weight loss drug VK2735 shows strong clinical promise with potential for dual-formulation therapy (injectable followed by oral maintenance). The company raised $500 million to fund pipeline development. With the obesity drug market projected to reach $77 billion by 2030, even a small 1.4% market share could generate $1.2 billion in revenue for Viking's $4 billion market cap, suggesting significant upside potential, though clinical trial risks remain.

Axe note: Viking’s new obesity drug could reshape its growth story if clinical trials hold up.

2026-10-02 10:10 • The Motley Fool Mixed Axe Cap view: Selective

The article argues that investors seeking robotics exposure should consider Teradyne, Zebra Technologies, and Rockwell Automation instead of Tesla. These three companies already deploy robots and automation solutions in real manufacturing environments, offering more tangible near-term robotics growth compared to Tesla's still-developing humanoid robot projects.

Axe note: For those interested in robotics, Tesla’s hype doesn’t match near-term reality, but Teradyne, Zebra Technologies, and Rockwell Automation offer clearer growth paths that matter globally and indirectly for the rand.